急性骨髄性白血病(AML)におけるマイクロバイオームのジスバイオシスと化学療法の耐性
Maojin Tian1, Hamed Soleimani Samarkhazan2, Seyed Shahabedin Alemohammad3
1Zibo Central Hospital, Binzhou Medical University, Zibo, Shandong, China. phytian@163.com.
Abstract:
AML often relapses due to chemotherapy resistance, increasingly linked to gut microbiome dysbiosis. Microbial drug modification, immune modulation, and metabolite-driven survival/epigenetic changes (e.g., SCFAs, kynurenine) promote resistance. Clinical data associate reduced diversity, loss of Faecalibacterium, and Enterococcus overgrowth with poorer outcomes. Microbiome interventions (FMT, probiotics, diet) show promise; priorities are standardizing methods and defining microbe-metabolite mechanisms to guide trials.
関連する概念動画
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


